Evangelia Petsalaki: New Systems Biology Approach Identifies Biomarkers in Thrombotic APS
Evangelia Petsalaki, Director of Oncology Data Science Innovation at GSK and Visiting Group Leader at EMBL-EBI, shared on LinkedIn about a recent article she and her colleagues co-authored, published in medRxiv, adding:
”We’re pleased to share our latest preprint on thrombotic primary antiphospholipid syndrome (APS).
In this study, we integrated plasma proteomics, whole-blood transcriptomics, machine learning and network-based analysis to investigate the molecular programmes associated with high-risk disease.
Across multiple complementary analyses, we found evidence for a complement- and interferon-associated thromboinflammatory programme linked to increasing antiphospholipid antibody burden and recurrent thrombosis. Integrating the data using multi-omics factor analysis and network propagation also connected circulating protein signatures to intracellular signalling pathways, providing a systems-level view of disease biology.
Among the findings, Complement Factor D (CFD) emerged as a candidate biomarker associated with recurrent thrombosis, although this will require validation in independent cohorts.
This work was a fantastic collaboration between colleagues at EMBL-EBI, the National and Kapodistrian University of Athens, and the Biomedical Sciences Research Center ‘Alexander Fleming’.
Many thanks to everyone involved, especially Srijith Sasikumar and Maria Tektonidou as well as our coauthors Michail Baltsiotis, Kleio-Maria Verrou, Georgia Rouni, Martina Samiotaki, Petros Sfikakis and the rest of the team.”
Title: Multi-omics and network propagation reveal latent innate immune programmes stratifying high-risk thrombotic primary antiphospholipid syndrome
Authors: Srijith Sasikumar, Michail Baltsiotis, Kleio-Maria Verrou, Georgia Rouni, Petros P. Sfikakis, Martina Samiotaki, Evangelia Petsalaki, Maria G. Tektonidou

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 16, 2026, 13:05Neil Morgan: Submit Your Abstract for BSHT 2027
-
Aug 16, 2026, 12:50Heba Youssef: Can Cefoperazone Cause Coagulopathy?
-
Aug 16, 2026, 12:35Mohammad Alkhalil: Stroke Remains a Dreaded Complication in TAVI
-
Aug 16, 2026, 12:16Jeff Schaffnit: The Power of Community in Rare Blood Disorders
-
Aug 16, 2026, 12:03Fawaz AlOtaibi: Can AI Replace Contrast CTA for Vascular Screening?
-
Aug 16, 2026, 10:31Erhabor Osaro: Critical Issues to Consider During the Clinical Blood Transfusion Process
-
Aug 16, 2026, 10:14Juan Manuel Cisneros Carrasco: The Architects Behind the Blood Donation System
-
Aug 16, 2026, 10:06Honoring the Life and Legacy of Dr. Reed Pyeritz – GADA Canada
-
Aug 16, 2026, 09:51Javier Amador-Castañeda: When a 32 Percent Reduction Tells Only Part of the Story